CorMedix (CRMD) 2025 Conference Transcript

CorMedix (CRMD) 2025 Conference June 05, 2025 03:45 PM ET Speaker0 Good? Alright. Hi, everybody. Try and squeeze in and find a seat where you can. Just a quick look at our forward looking statements. So who is CorMedix? Alright. We are a publicly traded, small cap, commercial stage biotech company, in the process of commercializing our lead product, DefenCath. DefenCath is an FDA approved, first in class, non antibiotic antimicrobial catheter lock solution initially indicated to reduce the incidence of cath ...